NICOX SA (ALCOX.PA) Stock Price & Overview

EPA:ALCOX • FR0013018124

0.4495 EUR
0 (-0.55%)
Last: Mar 6, 2026, 07:00 PM

The current stock price of ALCOX.PA is 0.4495 EUR. Today ALCOX.PA is down by -0.55%. In the past month the price increased by 31.05%. In the past year, price increased by 53.94%.

ALCOX.PA Key Statistics

52-Week Range0.2 - 0.65
Current ALCOX.PA stock price positioned within its 52-week range.
1-Month Range0.3305 - 0.569
Current ALCOX.PA stock price positioned within its 1-month range.
Market Cap
39.754M
P/E
N/A
Fwd P/E
3.36
EPS (TTM)
-0.36
Dividend Yield
N/A

ALCOX.PA Stock Performance

Today
-0.55%
1 Week
-7.03%
1 Month
+31.05%
3 Months
+47.86%
Longer-term
6 Months +25.21%
1 Year +53.94%
2 Years +13.22%
3 Years N/A
5 Years N/A
10 Years N/A

ALCOX.PA Stock Chart

NICOX SA / ALCOX Daily stock chart

ALCOX.PA Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to ALCOX.PA. When comparing the yearly performance of all stocks, ALCOX.PA is one of the better performing stocks in the market, outperforming 95.66% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
ALCOX.PA Full Technical Analysis Report

ALCOX.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ALCOX.PA. ALCOX.PA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ALCOX.PA Full Fundamental Analysis Report

ALCOX.PA Earnings

Next Earnings DateApr 28, 2026
Last Earnings DateOct 15, 2025
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
ALCOX.PA Earnings History

ALCOX.PA Forecast & Estimates

9 analysts have analysed ALCOX.PA and the average price target is 1.53 EUR. This implies a price increase of 240.38% is expected in the next year compared to the current price of 0.4495.

For the next year, analysts expect an EPS growth of 96% and a revenue growth 230% for ALCOX.PA


Analysts
Analysts84.44
Price Target1.53 (240.38%)
EPS Next Y96%
Revenue Next Year230%
ALCOX.PA Forecast & Estimates

ALCOX.PA Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

ALCOX.PA Financial Highlights

Over the last trailing twelve months ALCOX.PA reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS increased by 23.81% compared to the year before.


Income Statements
Revenue(TTM)3.32M
Net Income(TTM)-26.95M
Industry RankSector Rank
PM (TTM) N/A
ROA -179.67%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-71.43%
Sales Q2Q%-74.79%
EPS 1Y (TTM)23.81%
Revenue 1Y (TTM)13.86%
ALCOX.PA financials

ALCOX.PA Ownership

Ownership
Inst Owners4.12%
Shares88.44M
Float82.19M
Ins Owners0.33%
Short Float %N/A
Short RatioN/A
ALCOX.PA Ownership

About ALCOX.PA

Company Profile

ALCOX logo image Nicox SA is an ophthalmology company. The company is headquartered in Biot, Paca and currently employs 11 full-time employees. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.

Company Info

NICOX SA

Sundesk Sophia Antipolis, Batiment C, Emerald Square, rue Evariste Galois

BIOT PACA FR

Employees: 5

ALCOX Company Website

ALCOX Investor Relations

Phone: 33497245300

NICOX SA / ALCOX.PA FAQ

What does NICOX SA do?

Nicox SA is an ophthalmology company. The company is headquartered in Biot, Paca and currently employs 11 full-time employees. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.


What is the stock price of NICOX SA today?

The current stock price of ALCOX.PA is 0.4495 EUR. The price decreased by -0.55% in the last trading session.


Does NICOX SA pay dividends?

ALCOX.PA does not pay a dividend.


How is the ChartMill rating for NICOX SA?

ALCOX.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


On which exchange is ALCOX.PA stock listed?

ALCOX.PA stock is listed on the Euronext Paris exchange.


What do analysts say about NICOX SA (ALCOX.PA) stock?

9 analysts have analysed ALCOX.PA and the average price target is 1.53 EUR. This implies a price increase of 240.38% is expected in the next year compared to the current price of 0.4495.


What is the ownership structure of NICOX SA (ALCOX.PA)?

You can find the ownership structure of NICOX SA (ALCOX.PA) on the Ownership tab.